NEW YORK – Startup Savran Technologies aims to detect disease recurrence in triple negative breast cancer (TNBC) patients with its microfluidic platform, which isolates and quantifies circulating tumor cells (CTCs). The company believes the method could complement circulating tumor DNA (ctDNA)-based approaches to monitor for minimal residual disease (MRD).
Savran Technologies expects to integrate the microfluidic chip with a ctDNA assay offered by a liquid biopsy partner, with a goal to launch the combined platform in the US by 2022.